Navigation Links
Mylan Receives Tentative FDA Approval for Generic Version of Lipitor®
Date:2/2/2012

PITTSBURGH, Feb. 2, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited (formerly Matrix Laboratories Limited) has received tentative approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Atorvastatin Calcium Tablets, 10 mg (base), 20 mg (base), 40 mg (base) and 80 mg (base). Atorvastatin Calcium is the generic equivalent to Pfizer's Lipitor® Tablets, indicated for the prevention of cardiovascular disease and hypercholesterolemia.

Lipitor had U.S. sales of $8.2 billion for the twelve months ending Dec. 31, 2011, according to IMS Health.

Currently, Mylan has 173 ANDAs pending FDA approval representing $98.5 billion in annual sales, according to IMS Health. Forty-two of these pending ANDAs are potential first-to-file opportunities, representing $26.8 billion in annual brand sales, for the 12 months ending June 30, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.

 


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Mylan to Host Investor Day on Feb. 21, 2012, in New York City
2. Mylan Launches Innovative Version of Antiepileptic Drug Levetiracetam
3. Mylan Launches First Generic Version of Teveten® Tablets
4. Mylan Receives Approval for First-to-File Generic Keppra XR® Extended-Release Tablets
5. Mylan Receives WHO Approval for Innovative Second-Line-in-a-Box HIV/AIDS Treatment
6. Mylan Launches Generic Version of Toprol-XL® Tablets
7. Mylan Names John Thievon President of Dey Pharma
8. Mylan Launches Generic Version of Cyklokapron® Injection
9. Mylan Receives Tentative FDA Approval Through PEPFAR for First Heat-Stable, Fixed-Dose Combination of Atazanavir Sulfate and Ritonavir Tablets for HIV/AIDS
10. Mylan Launches Generic Version of Caduet® Tablets
11. Mylan Confirms First-to-File Patent Challenge Relating to Generess™ Fe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/13/2017)... Ind. , June 13, 2017 Zimmer Biomet ... musculoskeletal healthcare, today announced that the U.S. Food and Drug ... dated June 3, 2015 relating to its Zhejiang, ... "The successful clearance of the ... manufacturing facility is a measure of the progress ...
(Date:6/10/2017)... June 9, 2017  Shane K. Burchfield, DPM, is recognized by ... as a Podiatrist in Alabama . ... First Foot Care. He brings over 20 years of experience, as ... and healthcare, to his role. ... PC is pleased to welcome you to his practice," ...
(Date:6/8/2017)... 8, 2017  Less than a month ago, amateur ... 200,000 companies, including hospital networks, in over 150 countries. ... of the largest online extortion attempts ever recorded. With ... it is imperative that providers understand where the risks ... this — and many other very real cyber threats.  ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... June 28, 2017 , ... Eating disorders have the highest mortality rate of ... one person dies as a direct result from an eating disorder in the U.S. ... providers. The iaedp Foundation meets this challenge by offering what has become the leading ...
(Date:6/28/2017)... ... June 28, 2017 , ... Park Systems , ... Luncheon for all SEMICONWest attendees and Park customers on July 11, 2017 ... from Dr. Sang-il Park, Chairman & CEO of Park Systems, and Prof. Krishna ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... assistance and financial consultations to communities in northern Virginia and DC, is announcing ... help provide for patients with Alzheimer’s and other disorders that lead to memory ...
(Date:6/27/2017)... PA and London UK (PRWEB) , ... June 27, 2017 , ... ... applying to a clinical study is whether they can trust the sponsor to pay ... it is vital that sponsors and CROs establish payment strategies that encourage sites to ...
(Date:6/27/2017)... ... 27, 2017 , ... Building on the success of the ... sixth state to pass legislation which ensures that children can possess and use ... the states of Alabama, Arizona, Florida, Utah and Washington who have also approved ...
Breaking Medicine News(10 mins):